Acute Myeloid Leukemia (AML): Intensive Chemotherapy with or without Glasdegib or
AZA with or without Glasdegib
Does the drug Glasdegib help the survival of patients with Acute Myeloid Leukemia?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The purpose of this study is to determine if glasdegib is superior to placebo in combination
with azacitidine or cytarabine and daunorubicin in prolonging overall survival in
subjects with untreated AML.
Study Reference #: ILEU18020
Lead Researcher (Principal Investigator)
Lead Researcher: Jane Liesveld, MD
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search